May 01,2018

Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2018 Annual Meeting

Flatiron Health today announced 11 abstracts accepted for presentation at the 2018 American Society for Clinical Oncology (ASCO) Annual Meeting, which will be held June 1-5 in Chicago. The research, spanning multiple tumor types and areas of study, utilized Flatiron’s highly-curated, nationally-representative, real-world oncology datasets, the largest in the United States.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 17,2018

Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 1-5 in Chicago; and the 23rd Annual Congress of the European Hematology Association (EHA), scheduled for June 14-17 in Stockholm.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 17,2018

Astellas Announces Abstracts Highlighting Growing Oncology Portfolio to be Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that a wide selection of abstracts highlighting the Company’s diverse oncology portfolio across a broad range of cancers have been accepted for oral and poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5 in Chicago.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 01,2018

Dayton Physicians Network Announces Expanded Relationship with Flatiron Health to Streamline Across the OncoCloudTM Suite

Dayton Physicians Network (DPN) and Flatiron Health today announced that they have expanded their partnership with the addition of OncoEMR, OncoTrials and Oncology Care Model services in addition to DPN’s use of OncoAnalytics from Flatiron’s OncoCloudTM suite.

COLLABORATION PARTNERSHIP

#institution

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 25,2018

Incyte Highlights Abstracts Accepted for Presentation at the 2018 ASCO Annual Meeting

Incyte Corporation (Nasdaq:INCY) announces that multiple abstracts from its research and development portfolio will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois from June 1-5, 2018.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 01,2018

Patient experience, efficiency and cost effects of digital patient monitoring evaluated at the new study by Helsinki University Hospital

Urology department of Helsinki University Hospital has started a new research project ePRO-PCaRP/RT evaluating patient experience, efficiency and cost effects of digital patient monitoring among prostate cancer patients. Kaiku Health application and an electronic questionnaire is used to evaluate the patient’s quality of life. Over 600 prostate cancer patients treated with both surgery and radiotherapy will be invited to participate in the research. Duration of this randomized phase III trial is approximately two years and the results will be published in relevant scientific journals.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 02,2018

The Latest Advancements: Artificial Intelligence in Dermatology and Cancer

Recently, there has been a considerable amount of hype surrounding artificial intelligence (particularly in the field of dermatology), which primarily discusses the potential benefits/challenges of the technology along with expected release timelines. This article from MetaOptima gives examples to the advanced technologies and AI in dermatology, such as IBM Watson and its own DermEngine, for detecting skin cancer.

#ai/software

#telehealth

View Analyst & Ambassador Comments
Go to original news
Mar 16,2018

Mayo Clinic's Clinical Trial Matching Project Sees Higher Enrollment in Breast Cancer Trials through Use of Artificial Intelligence

Mayo Clinic and IBM Watson Health (NYSE: IBM) have unveiled results from early use of the Watson for Clinical Trial Matching, an IBM cognitive computing system. Use of this system in the Mayo Clinic oncology practice has been associated with more patients enrolled in Mayo’s breast cancer clinical trials. The organizations also announced an agreement that aims to extend and expand training and use of the system. Training on trials for additional cancer types is already underway. Currently, the system is trained to support clinical trial matching for breast, lung and gastrointestinal cancers.

PRODUCT

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Mar 07,2018

Novartis expands alliance with Science 37 to advance virtual clinical trials program

Novartis today announced an additional strategic alliance with Science 37, a leader in decentralized clinical trial technology and design, to initiate up to 10 new clinical trials over the next three years. The studies will blend virtual and traditional models, with increasing degrees of decentralization towards a mostly "site-less" model. Novartis was an early investor in Science 37 and together we have already initiated virtual trials for cluster headache, acne and nonalcoholic steatohepatitis (NASH). The new Novartis decentralized trials are expected to begin later this year in the United States (US) in the areas of dermatology, neuroscience and oncology, leveraging Science 37's proprietary Network Oriented Research Assistant (NORA®) technology, which enables patients to participate in studies using mobile devices and telemedicine services.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Mar 07,2018

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Andy Schmeltz, Global President, Oncology, and Chris Boshoff, Senior Vice President and Head, Immuno-Oncology, Early Development and Translational Oncology, at the Cowen and Company 38th Annual Healthcare Conference on Wednesday, March 14, 2018 at 10:40 a.m. Eastern Daylight Time.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY